ChromaDex Co. (NASDAQ:CDXC - Get Free Report) shares gapped up prior to trading on Friday . The stock had previously closed at $6.66, but opened at $7.05. ChromaDex shares last traded at $6.77, with a volume of 168,813 shares trading hands.
Analyst Upgrades and Downgrades
Several equities analysts have weighed in on CDXC shares. Roth Mkm raised their target price on shares of ChromaDex from $6.00 to $8.00 and gave the company a "buy" rating in a report on Wednesday, November 6th. HC Wainwright raised their target price on shares of ChromaDex from $6.00 to $8.00 and gave the company a "buy" rating in a report on Monday, November 4th. Finally, StockNews.com downgraded shares of ChromaDex from a "strong-buy" rating to a "buy" rating in a report on Monday, November 18th.
Check Out Our Latest Stock Analysis on ChromaDex
ChromaDex Stock Performance
The stock has a market capitalization of $513.27 million, a PE ratio of 672.67 and a beta of 2.16. The company's fifty day simple moving average is $5.36 and its two-hundred day simple moving average is $3.86.
ChromaDex (NASDAQ:CDXC - Get Free Report) last issued its quarterly earnings results on Thursday, October 31st. The company reported $0.02 EPS for the quarter. The business had revenue of $25.58 million during the quarter, compared to the consensus estimate of $23.70 million. ChromaDex had a net margin of 1.62% and a return on equity of 4.85%. During the same period in the previous year, the firm posted ($0.01) earnings per share. Sell-side analysts forecast that ChromaDex Co. will post 0.04 EPS for the current fiscal year.
Institutional Investors Weigh In On ChromaDex
Hedge funds and other institutional investors have recently modified their holdings of the company. Miracle Mile Advisors LLC acquired a new stake in shares of ChromaDex in the second quarter worth approximately $27,000. The Manufacturers Life Insurance Company acquired a new stake in shares of ChromaDex in the second quarter worth approximately $31,000. Merriman Wealth Management LLC acquired a new stake in shares of ChromaDex in the second quarter worth approximately $32,000. FMR LLC acquired a new stake in shares of ChromaDex in the third quarter worth approximately $55,000. Finally, SG Americas Securities LLC acquired a new stake in shares of ChromaDex in the third quarter worth approximately $61,000. 15.41% of the stock is currently owned by hedge funds and other institutional investors.
About ChromaDex
(
Get Free Report)
ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.
Recommended Stories
Before you consider ChromaDex, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ChromaDex wasn't on the list.
While ChromaDex currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
